Insightful Analysis on Economics, Markets & Global Affairs
- EUR/USDLoading…————
- XAU/USDLoading…————
- USD/TRYLoading…————
- EUR/TRYLoading…————
- XAU/TRYLoading…————
- Brent OilLoading…————
- S&P 500Loading…————
- UST Yield 10yLoading…————
- BIST 100Loading…————
- VIXLoading…————
Editor's Pick
Trending
Aug 31, 2026
Asian refiners from China to South Korea are buying Argentine crude to avoid the Middle East, reshaping global oil trade in real time.
Sep 3, 2026
Uber will eliminate 10% of its workforce to flatten management and funnel money into self-driving cars, and Wall Street approved immediately.
Latest
Uber will eliminate 10% of its workforce to flatten management and funnel money into self-driving cars, and Wall Street approved immediately.
Uber will eliminate 10% of its workforce to flatten management and funnel money into self-driving cars, and Wall Street approved immediately.
Medtronic's AFib treatment technology grew 88% globally in one quarter, pushing the company to raise its full-year outlook.
Medtronic's AFib treatment technology grew 88% globally in one quarter, pushing the company to raise its full-year outlook.
A Cyclospora outbreak is set to wipe out a quarter of profit growth at one of America's quietest food success stories.
A Cyclospora outbreak is set to wipe out a quarter of profit growth at one of America's quietest food success stories.
Affirm's best quarter ever sent its stock down 4%. The reason is what comes next: a physical card with rewards math that CEO Max Levchin calls "really, really hard science."
Affirm's best quarter ever sent its stock down 4%. The reason is what comes next: a physical card with rewards math that CEO Max Levchin calls "really, really hard science."
Phibro Animal Health posted a strong first full year after its big acquisition, but thin cash flow and slowing growth raise real questions about what comes next.
Phibro Animal Health posted a strong first full year after its big acquisition, but thin cash flow and slowing growth raise real questions about what comes next.
Medtronic and its newly spun-off diabetes arm Minimed both raised their full-year outlooks after stronger-than-expected sales across the board.
Medtronic and its newly spun-off diabetes arm Minimed both raised their full-year outlooks after stronger-than-expected sales across the board.
Teva wants worldwide rights to an FDA-reviewed agitation drug, picking it up from a bankruptcy sale for up to $125 million.
Teva wants worldwide rights to an FDA-reviewed agitation drug, picking it up from a bankruptcy sale for up to $125 million.
ONEOK is buying Brazos Midstream's Permian pipeline assets for $4.425bn, betting that America's most productive oil patch still has years of growth ahead.
ONEOK is buying Brazos Midstream's Permian pipeline assets for $4.425bn, betting that America's most productive oil patch still has years of growth ahead.
